Further, addressing intratumoral heterogeneity in endometrial tumors is crucial, particularly whether amplicon-based NGS assays can detect ERBB2 amplification if only a small portion of the tumor is amplified, even with overall tumor cellularity greater than 30%. The gene discussed is ERBB2; the disease is neoplasm.